This is a new Research Program at the Stanford Cancer Center that has been established to promote collaborations among clinical and basic scientists to develop novel diagnostic and therapeutic approaches for cancer. The program consists of 41 members from 12 departments and 3 schools within the University and brings together chemists, biologists, statisticians and translational and clinical researchers with a common interest in the development of new cancer therapies. The Program has five major components: target identification and validation;drug discovery and delivery;mechanisms of drug action;molecular diagnostics;and clinical translational research. Research by program members has identified a novel synthetic chemistry approach to overcome taxol drug resistance, utilized carbon nanotechnology for the development of targeted delivery of Taxol (paclitaxel) or Doxorubicin, discovered that the inhibition of alpha PKC protects against breast cancer metastasis, defined genetic mechanisms for regulation of the MDR1/ABCB1 gene, developed a new technology for the nanoscale measurement of proteins for molecular diagnostics, applied high-throughput technologies to identify new agents that target the hedgehog pathway, and identified novel adenoviral based vectors for gene delivery to the liver. The Program is highly interactive through annual retreats, monthly research meetings, bi-annual faculty meetings, bi-annual student-sponsored symposia and invited speakers and symposia with pharmaceutical companies. The Program has catalyzed interactions leading to multi-investigator program awards including: a Leukemia and Lymphoma SCOR grant, a Department of Defense grant and an NIH Major Equipment Instrument Grant. Dr. Dean Felsher, Program Leader, is a physician scientist who is a leader in elucidating mechanisms of oncogene addiction through the use of transgenic animal models of lymphoma, hepatoma, osteosarcoma and lung adenocarcinoma. Dr. Branimir Sikic, Program Co-Leader, is a physician scientist whose research focuses on the pharmacology of drug resistance and who has been instrumental in implementing Phase I and II clinical trials. This program has the goal of conducting first-in- human Phase I trials of novel agents based on the best science.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA124435-07
Application #
8475446
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
7
Fiscal Year
2013
Total Cost
$13,987
Indirect Cost
$4
Name
Stanford University
Department
Type
DUNS #
009214214
City
Stanford
State
CA
Country
United States
Zip Code
94305
Patel, Manali I; Sundaram, Vandana; Desai, Manisha et al. (2018) Effect of a Lay Health Worker Intervention on Goals-of-Care Documentation and on Health Care Use, Costs, and Satisfaction Among Patients With Cancer: A Randomized Clinical Trial. JAMA Oncol 4:1359-1366
Trieu, Vanessa; Pinto, Harlan; Riess, Jonathan W et al. (2018) Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck. Oncologist 23:764-e86
Kuonen, François; Surbeck, Isabelle; Sarin, Kavita Y et al. (2018) TGF?, Fibronectin and Integrin ?5?1 Promote Invasion in Basal Cell Carcinoma. J Invest Dermatol 138:2432-2442
Gee, Marvin H; Han, Arnold; Lofgren, Shane M et al. (2018) Antigen Identification for Orphan T Cell Receptors Expressed on Tumor-Infiltrating Lymphocytes. Cell 172:549-563.e16
Malta, Tathiane M; Sokolov, Artem; Gentles, Andrew J et al. (2018) Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. Cell 173:338-354.e15
Banerjee, Imon; Gensheimer, Michael Francis; Wood, Douglas J et al. (2018) Probabilistic Prognostic Estimates of Survival in Metastatic Cancer Patients (PPES-Met) Utilizing Free-Text Clinical Narratives. Sci Rep 8:10037
Thorsson, Vésteinn; Gibbs, David L; Brown, Scott D et al. (2018) The Immune Landscape of Cancer. Immunity 48:812-830.e14
Rogers, Zoë N; McFarland, Christopher D; Winters, Ian P et al. (2018) Mapping the in vivo fitness landscape of lung adenocarcinoma tumor suppression in mice. Nat Genet 50:483-486
Nair, Viswam S; Sundaram, Vandana; Desai, Manisha et al. (2018) Accuracy of Models to Identify Lung Nodule Cancer Risk in the National Lung Screening Trial. Am J Respir Crit Care Med 197:1220-1223
She, Richard; Jarosz, Daniel F (2018) Mapping Causal Variants with Single-Nucleotide Resolution Reveals Biochemical Drivers of Phenotypic Change. Cell 172:478-490.e15

Showing the most recent 10 out of 322 publications